DEA Extends Controlled Substance Reexport Deadline to One Year
Published Date: 10/1/2026
Proposed Rule
Summary
The DEA is proposing to give companies more time—up to 365 days instead of 180—to send controlled substances back out of the European Economic Area. This change helps businesses avoid rushing and reduces stress around shipping deadlines. If you handle these substances, you can share your thoughts by November 30, 2026.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Reexport deadline doubled to 365 days
If you export controlled substances from the United States (except for reexports among European Economic Area countries), the DEA proposes to change the reexport deadline from 180 days to 365 calendar days after the shipment was released by a U.S. customs officer. DEA says this will largely eliminate the need to notify DEA and request one-time waivers; it estimates a $116.20 saving per avoided waiver event, $348.60 in annual savings (about $349), and a present value savings of $2,451 at a 7% discount over 10 years. Comments on the proposal are due by November 30, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-19839, Jorge J. Figueroa, M.D.; Decision and Order
Dr. Jorge J. Figueroa from New Jersey lost his DEA registration because he was kicked out of Medicare, Medicaid, and other federal health programs. He didn’t ask for a hearing, so the DEA made the decision official. This means he can’t legally handle controlled substances anymore, effective immediately, impacting his medical practice and income.
2026-19840, Christopher Nadorff, M.D.; Decision and Order
Dr. Christopher Nadorff from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
2026-19842, JT Medical, LLC; Decision and Order
JT Medical, LLC tried to get a DEA registration to handle marijuana but didn’t meet the rules because they couldn’t prove they had a real supply deal or a secure storage cabinet. Since they didn’t respond to the government’s concerns on time, their application was denied. This means JT Medical can’t legally handle marijuana products, and anyone working with them should look for other options.
Previous / Next Documents
Previous: 2026-20079, International Traffic in Arms Regulations (ITAR): Review of the U.S. Munitions List and Related Definitions and License Exemptions
The U.S. Department of State wants to update the rules that control the export of military gear and tech to focus only on the most sensitive stuff. They’re making the list clearer, removing some items, and adding new ways to skip licenses for certain exports. If you deal with defense exports, get ready to review these changes and send your thoughts by November 30, 2026!
Next: 2026-20087, Clarification of Certain Mariner Training Requirements
The Coast Guard wants to simplify training rules for certain mariners, like Masters and Officers in charge of smaller vessels and engineers with big engines. They’re removing six outdated or duplicate requirements to make things clearer and easier while matching international standards. If you’re affected, get ready to share your thoughts by December 30, 2026—no extra costs, just smoother sailing ahead!